Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer.

× No keyword cloud information.

7 in total

1. Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer.

Authors: Shuliang Yu; Qian Meng; Huihui Hu; Man Zhang
Journal: Int J Clin Exp Pathol Date: 2014-08-15

2. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer.

Authors: Shujun Zhang; Lutao Du; Lishui Wang; Xiumei Jiang; Yao Zhan; Juan Li; Keqiang Yan; Weili Duan; Yinghui Zhao; Lili Wang; Yunshan Wang; Yuliang Shi; Chuanxin Wang
Journal: J Cell Mol Med Date: 2018-11-23 Impact factor: 5.310

3. MicroRNA-3648 Is Upregulated to Suppress TCF21, Resulting in Promotion of Invasion and Metastasis of Human Bladder Cancer.

Authors: Wenrui Sun; Shi Li; Yuan Yu; Honglei Jin; Qipeng Xie; Xiaohui Hua; Shuai Wang; Zhongxian Tian; Huxiang Zhang; Guosong Jiang; Chuanshu Huang; Haishan Huang
Journal: Mol Ther Nucleic Acids Date: 2019-04-14 Impact factor: 8.886

High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer.

1. Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer.

2. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer.

3. MicroRNA-3648 Is Upregulated to Suppress TCF21, Resulting in Promotion of Invasion and Metastasis of Human Bladder Cancer.

4. Upregulation of NPL4 promotes bladder cancer cell proliferation by inhibiting DXO destabilization of cyclin D1 mRNA.

5. miR-492 Promotes Cancer Progression by Targeting GJB4 and Is a Novel Biomarker for Bladder Cancer.

6. Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma.

7. Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States.